Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside (NASDAQ:ALMS)
· seekingalpha.com
Alumis Inc. faces high biotech risk after a lupus trial setback, but envudeucitinib TYK2 potential remains. Click for more on ALMS stock.
Alumis Inc. ( ALMS ) is still a late-stage biopharmaceutical company with no commercial product. So, there's no getting around the risk here. The company is bui...